基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Since 1984, Josep Rocas Sorolla, PhD, has been leading many R&D departments of different pharmaceutical and chemical companies like Synthesia, Lab. Hosbon (now Sanofi), Sandoz (now Clariant and Novartis). In Clariant, he was R&D International Manager for the Leather Sector in Switzerland and Germany. Later, he was in Merquinsa (now Lubrizol) and Morchem, developing ecofriendly and water based high performance polyurethanes. Afterwards, in the Institut Químic de Sarrià, was coordinating the R&D groups and managing the industrial R&D projects and technology transfer. In 2005, he founded ECOPOL TECH to provide R&D and manufacturing services. Ecopol Tech is focused on environmentally friendly nanostructured polymers. The industrial division supplies specialty additives, coatings and adhesives, and micro- or nano-capsules for many sectors. In the cosmetics division, Ecopol Tech provides specialty functional polymers, and delivery systems based on micro and nanocapsules. In the pharmaceutical division, a unique nanoencapsulation platform (EcostratarR) for smart drug delivery has been concept proved for tackling several diseases. This biodegradable and safety platform provides stimuli responsive multiwalled nanocapsules easy to prepare and functionalize (with bio and chemical ligands) using a proprietary self-stratifiable, self-emulsifiable system. It is also fast scalable to bulk production. He is author of several patents and articles.
ECOPOL TECH NANOBIOTECH IN ONE PAGE. ECOSTRATAR TECHNOLOGY PLATFORM.
Ecopol Tech (2005) is a Nano Biotech company intensive in R&D, with expertise in nanostructured polymers, mainly based on polyurethane hybrid chemistry. Expertise in multifunctional and multiwalled polymeric nanoencapsulation. Proprietary of industrial scalable platform for smart drug delivery systems. ECOSTRATAR TECHNOLOGY. Unique easy to functionalize nanocapsules with chemical ligands or bioligands for selective targeting. Self-emulsifiable by self-stratification (surfactants free), biocompatible, biodegradable. Nanocapsules with special surface design for targeting inflammatory diseases. Not detectable in blood pH to avoid reticuloendothelial system and to be long circulating. Smart accumulation in dysregulated cells with acidic environment (inflamed zones), faster internalization and smart delivery on these cells using overexpressed intracellular biologicals. Very robust due to polymer crosslinking until target and internalization. We are active in oncology, immunotherapy, virology, regenerative medicine, cardiovascular, infectious diseases and brain diseases. We have different proof of concepts in vitro and in vivo, 2 patents, several articles and Congresses presentations. In oncology we have tackled breast, lung, neuroblastoma, and now melanoma with different approaches (targeted nanotherapy and targeted nanoimmunology). In immunotherapy we deliver selectively to dendritic cells, to fight against autoimmune diseases with immunosuppressants, or with immunopotentiators to fight against cancer and infections. In virology we area active against VIH to eliminate latent reservoir, and to Hepatitis B with gene therapy (oligonucleotides) to liver endothelium. In regenerative medicine we developed a multifunctional nanocapsule loaded with antibiotic and decorated with an osseointegrative peptide to coat titanium for prothesis. In cardiovascular we have nanocapsules that deliver selectively in endothelium with potential to fight against arteriosclerosis and other diseases (maybe COVID) depending on loading. We are running a project to tackle selectively resistant bacteria with multifunctional nanocapsules. Recently we are trying to cross the BBB to fight against children’s diseases like Rett Syndrome, with potential for other diseases. The nanocapsules are biocompatible, biodegradable (metabolizable) and nontoxic. We are collaborating with the best R&D groups of Barcelona University (Scientific Parc of Barcelona) and the best R&D groups of the more important Hospitals. We have co-driven 3 Industrial PhD´s. More than 12 years of experience in Nanomedicines, and more than 30 years’ experience in different sectors (Pharmaceutical and polymer chemistry). We also collaborate with international R&D groups like Boston University, Penn University, Hunimed University, PSL University Paris, Luxembourg Institute of Health and ETH Zürich.
We have fully equipped laboratories with a clean room area for synthesis and manufacturing. Fully equipped for the chemical characterization of our nanomaterials (nanomedicines).
Josep Rocas, PhD, is the Founder & CEO, and expert in different disciplines. Among other responsibilities in R&D departments of chemical and pharmaceutical companies, he was worldwide R&D Head of Leather Business in Sandoz, now Novartis and Clariant, in Basel (Switzerland) and Leinfelden (Germany). After being Responsible of R&D and Technology Transfer in the university (IQS), he founded Ecopol Tech (www.ecopoltech)
Research Interests
Papers共 14 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Yuxiang Zhou,David Hou,Cristina Cusco Marigo,Joaquín Bonelli,Pau Rocas, Fangzhou Cheng, Xiaoqiu Yang,Josep Rocas, Naomi M. Hamberg,Jingyan Han
Joaquín Bonelli,María Velasco-de Andrés, Neus Isidro,Cristina Bayó, Sergi Chumillas,Laura Carrillo-Serradell,Sergi Casadó-Llombart, Cheryl Mok,Daniel Benítez-Ribas,Francisco Lozano,Josep Rocas,Vicente Marchán
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINEno. 2 (2018)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn